[(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance

Overview

Journal Bioconjug Chem

Publisher American Chemical Society

Specialty Biochemistry

Date 2016 Jun 9

PMID 27270097

Citations 10

Authors

Ying Chen

Ala Lisok

Samit Chatterjee

Bryan Wharram

Mrudula Pullambhatla

Yuchuan Wang

George Sgouros

Ronnie C Mease

Martin G Pomper

Affiliations

Soon will be listed here.

Abstract

Prostate-specific membrane antigen (PSMA) is overexpressed in the epithelium of prostate cancer and nonprostate solid tumor neovasculature. PSMA is increasingly utilized as a target for cancer imaging and therapy. Here, we report the synthesis and in vivo biodistribution of a low-molecular-weight PSMA-based imaging agent, 2-[3-(1-carboxy-5-{3-[1-(2-[(18)F]fluoroethyl)-1H-1,2,3-triazol-yl]propanamido}pentyl)ureido]pentanedioic acid ([(18)F]YC-88), containing an [(18)F]fluoroethyl triazole moiety. [(18)F]YC-88 was synthesized from 2-[(18)F]fluoroethyl azide and the corresponding alkyne precursor in two steps using either a one- or two-pot procedure. Biodistribution and positron emission tomography (PET) imaging were performed in immunocompromised mice using isogenic PSMA(+) PC3 PIP and PSMA(-) PC3 flu xenografts. YC-88 exhibited high affinity for PSMA as evidenced by a Ki value of 12.9 nM. The non-decay corrected radiochemical yields of [(18)F]YC-88 averaged 14 ± 1% (n = 5). Specific radioactivities ranged from 320 to 2,460 Ci/mmol (12-91 GBq/μmol) with an average of 940 Ci/mmol (35 GBq/μmol, n = 5). In an immunocompromised mouse model, [(18)F]YC-88 clearly delineated PSMA(+) PC3 PIP prostate tumor xenografts on imaging with PET. At 1 h postinjection, 47.58 ± 5.19% injected dose per gram of tissue (% ID/g) was evident within the PSMA(+) PC3 PIP tumor, with a ratio of 170:1 of uptake within PSMA(+) PC3 PIP to PSMA(-) PC3 flu tumor placed in the opposite flank. The tumor-to-kidney ratio at 2 h postinjection was 4:1. At or after 30 min postinjection, minimal nontarget tissue uptake of [(18)F]YC-88 was observed. Compared to [(18)F]DCFPyL, which is currently in clinical trials, the uptake of [(18)F]YC-88 within the kidney, liver, and spleen was significantly lower at all time-points studied. At 30 min and 1 h postinjection, salivary gland uptake of [(18)F]YC-88 was significantly less than that of [(18)F]DCFPyL. [(18)F]YC-88 is a new PSMA-targeted PET agent synthesized utilizing click chemistry that demonstrates high PSMA(+) tumor uptake in a xenograft model. Because of its low uptake in the kidney, rapid clearance from nontarget organs, and relatively simple one-pot, two-step radiosynthesis, [(18)F]YC-88 is a viable new PET radiotracer for imaging PSMA-expressing lesions.

Citing Articles

Preparation, Biological Evaluation, and First-in-Human Single-Photon Emission Computed Tomography (SPECT) Study of Tc-Labeled Prostate-Specific Membrane Antigen (PSMA)-Targeted Radiotracers Containing Triazole with Reduced Kidneys Accumulation.

Xiao D, Han P, Jiang Y, Duan X, Ruan Q, Zhang Z ACS Pharmacol Transl Sci. 2024; 7(5):1335-1347.

PMID: 38751628 PMC: 11092200. DOI: 10.1021/acsptsci.4c00012.

Click Chemistry and Radiochemistry: An Update.

Bauer D, Cornejo M, Hoang T, Lewis J, Zeglis B Bioconjug Chem. 2023; 34(11):1925-1950.

PMID: 37737084 PMC: 10655046. DOI: 10.1021/acs.bioconjchem.3c00286.

Multi-timepoint imaging with PSMA-targeted [F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging.

Sheikhbahaei S, Bello Martinez R, Markowski M, Eisenberger M, Pienta K, Reyes D Ann Nucl Med. 2023; 37(4):246-254.

PMID: 36857019 DOI: 10.1007/s12149-023-01823-2.

The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review.

Rizzo A, Racca M, DallArmellina S, Rescigno P, Banna G, Albano D Cancers (Basel). 2023; 15(2).

PMID: 36672305 PMC: 9857064. DOI: 10.3390/cancers15020355.

A fluorine-18 labeled radiotracer for PET imaging of γ-glutamyltranspeptidase in living subjects.

Gao D, Miao Y, Ye S, Lu C, Lv G, Li K RSC Adv. 2022; 11(31):18738-18747.

PMID: 35478654 PMC: 9033604. DOI: 10.1039/d1ra01324f.

References

Rowe S, Gorin M, Hammers H, Som Javadi M, Hawasli H, Szabo Z . Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. Ann Nucl Med. 2015; 29(10):877-82. PMC: 4666821. DOI: 10.1007/s12149-015-1017-z. View

Huang X, Bennett M, Thorpe P . Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate. 2004; 61(1):1-11. DOI: 10.1002/pros.20074. View

Chen Y, Pullambhatla M, Foss C, Byun Y, Nimmagadda S, Senthamizhchelvan S . 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011; 17(24):7645-53. PMC: 3243762. DOI: 10.1158/1078-0432.CCR-11-1357. View

Szabo Z, Mena E, Rowe S, Plyku D, Nidal R, Eisenberger M . Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015; 17(4):565-74. PMC: 4531836. DOI: 10.1007/s11307-015-0850-8. View

Barinka C, Byun Y, Dusich C, Banerjee S, Chen Y, Castanares M . Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem. 2008; 51(24):7737-43. PMC: 5516903. DOI: 10.1021/jm800765e. View

Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K . Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015; 17(4):575-84. PMC: 4493776. DOI: 10.1007/s11307-015-0866-0. View

Cho S, Gage K, Mease R, Senthamizhchelvan S, Holt D, Jeffrey-Kwanisai A . Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012; 53(12):1883-91. PMC: 3742115. DOI: 10.2967/jnumed.112.104661. View

Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V . Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997; 57(17):3629-34. View

Silver D, Pellicer I, Fair W, Heston W, Cordon-Cardo C . Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997; 3(1):81-5. View

10.

Afshar-Oromieh A, Haberkorn U, Schlemmer H, Fenchel M, Eder M, Eisenhut M . Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2013; 41(5):887-97. DOI: 10.1007/s00259-013-2660-z. View

11.

Humenik M, Huang Y, Wang Y, Sprinzl M . C-terminal incorporation of bio-orthogonal azide groups into a protein and preparation of protein-oligodeoxynucleotide conjugates by Cu'-catalyzed cycloaddition. Chembiochem. 2007; 8(10):1103-6. DOI: 10.1002/cbic.200700070. View

12.

Mease R, Dusich C, Foss C, Ravert H, Dannals R, Seidel J . N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008; 14(10):3036-43. PMC: 3078104. DOI: 10.1158/1078-0432.CCR-07-1517. View

13.

Chang S, Reuter V, Heston W, Bander N, Grauer L, Gaudin P . Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999; 59(13):3192-8. View

14.

Eiber M, Nekolla S, Maurer T, Weirich G, Wester H, Schwaiger M . (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer. Abdom Imaging. 2014; 40(6):1769-71. DOI: 10.1007/s00261-014-0301-z. View

15.

Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C . [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012; 39(6):1085-6. DOI: 10.1007/s00259-012-2069-0. View

16.

Chen Y, Foss C, Byun Y, Nimmagadda S, Pullambhatla M, Fox J . Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008; 51(24):7933-43. PMC: 2631656. DOI: 10.1021/jm801055h. View

17.

Cheng Y, Prusoff W . Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973; 22(23):3099-108. DOI: 10.1016/0006-2952(73)90196-2. View

18.

Rowe S, Gage K, Faraj S, Macura K, Cornish T, Gonzalez-Roibon N . ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. J Nucl Med. 2015; 56(7):1003-1010. PMC: 4659400. DOI: 10.2967/jnumed.115.154336. View

19.

Kozikowski A, Zhang J, Nan F, Petukhov P, Grajkowska E, Wroblewski J . Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem. 2004; 47(7):1729-38. DOI: 10.1021/jm0306226. View

20.

Chen Y, Dhara S, Banerjee S, Byun Y, Pullambhatla M, Mease R . A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun. 2009; 390(3):624-9. PMC: 2787846. DOI: 10.1016/j.bbrc.2009.10.017. View